Thursday, January 18, 2018
Company News: Page (1) of 1 - 01/08/18 Email this story to a friend. email article Print this page (Article printing at page facebook
NX Prenatal to Present at the 2018 Society for Maternal Fetal Medicine Annual Meeting in Dallas, Texas
Preterm Risk Assessment at 10-12 weeks has potential to revolutionize clinical care pathways and provide high impact cost savings
(January 08, 2018)

LOUISVILLE, Ky. and HOUSTON, Jan. 8, 2018 /PRNewswire/ -- NX Prenatal Inc., a US based molecular diagnostics company utilizing its proprietary NeXosome® technology for early warning of adverse pregnancy outcomes, announced today that data from its ongoing validation studies will be presented at the Society of Maternal Fetal Medicine's (SMFM) annual meeting held in Dallas, TX, January 29th through February 3rd, 2018. The presentation will describe results from a multicenter study of samples obtained from 186 pregnant mothers designed to validate the performance of functional proteomic biomarker panels that are already unique in their expression profiles at 10-12 weeks gestation among women who go on to deliver spontaneously at less than 35 weeks. (PRNewsFoto/NX Prenatal Inc.)

NX Prenatal's approach is of revolutionary potential as it represents a non-invasive 'biopsy' of maternal and fetal tissues via blood testing in the first trimester of pregnancy.   "As with any disease, providing early warning biomarker signals for preterm birth risk can augment physicians' clinical assessment and provide them critical new tools for optimizing their patients' care plans," added Dr. Kevin Rosenblatt, Chief Medical and Scientific Officer of NX Prenatal.  "The field has been seeking to provide new decision support tools that can be used in the first trimester.  Our NeXosome technology allows us to evaluate an enriched sub-fraction of maternal plasma which contains valuable exosome-associated signals originating from maternal and fetal tissues.  Our studies continue to demonstrate that this can yield important risk stratification information at week 10-12 of gestation from a blood sample drawn during a normal pregnancy office visit." NX Prenatal intends this to be the first of several risk-assessment tests that can be performed early in pregnancy to enable personalized care strategies in support of healthy pregnancy outcomes.

The invited presentation at the SMFM annual meeting will occur at 2:30pm local time on February 1, 2018 in the Chantilly Ballroom East at the Hilton Anatole hotel in Dallas, TX.

About NX Prenatal
NX Prenatal Inc. (NXPN) is a private US based molecular diagnostics company.  The company's NeXosome® technology harvests biologically active and stable microparticles, such as exosomes, from the maternal bloodstream, to provide a real-time and non-invasive view of changing maternal and fetal tissues.  This technology is enabling the development of a series of early warning blood tests for pregnancies that may result in a variety of adverse outcomes, such as spontaneous preterm birth.

Cision View original content with multimedia:

SOURCE NX Prenatal Inc.

Copyright 2014 PR Newswire. All Rights Reserved

Page: 1

Related Keywords: Inc.,Medicine,Disease,Pregnancy,Surgery,Medication,Pregnancy,Science,Medical,Women,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines